10,751 Shares in Dyne Therapeutics, Inc. (NASDAQ:DYN) Acquired by SG Americas Securities LLC

SG Americas Securities LLC acquired a new position in Dyne Therapeutics, Inc. (NASDAQ:DYNGet Rating) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 10,751 shares of the company’s stock, valued at approximately $74,000.

A number of other large investors have also added to or reduced their stakes in the company. Amalgamated Bank purchased a new position in Dyne Therapeutics during the 1st quarter valued at $35,000. UBS Group AG boosted its holdings in Dyne Therapeutics by 2,368.9% during the 1st quarter. UBS Group AG now owns 10,172 shares of the company’s stock valued at $98,000 after acquiring an additional 9,760 shares during the period. Nisa Investment Advisors LLC boosted its holdings in Dyne Therapeutics by 4,034.6% during the 1st quarter. Nisa Investment Advisors LLC now owns 14,347 shares of the company’s stock valued at $138,000 after acquiring an additional 14,000 shares during the period. MetLife Investment Management LLC boosted its holdings in Dyne Therapeutics by 57.0% during the 1st quarter. MetLife Investment Management LLC now owns 19,766 shares of the company’s stock valued at $191,000 after acquiring an additional 7,180 shares during the period. Finally, GSA Capital Partners LLP boosted its holdings in Dyne Therapeutics by 20.5% during the 1st quarter. GSA Capital Partners LLP now owns 27,943 shares of the company’s stock valued at $269,000 after acquiring an additional 4,750 shares during the period. Institutional investors own 90.22% of the company’s stock.

Dyne Therapeutics Price Performance

Shares of NASDAQ DYN opened at $9.53 on Friday. The stock has a market capitalization of $496.77 million, a P/E ratio of -2.72 and a beta of 0.05. Dyne Therapeutics, Inc. has a 1-year low of $4.30 and a 1-year high of $16.39. The business has a fifty day moving average price of $11.74 and a 200 day moving average price of $11.28.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. StockNews.com assumed coverage on Dyne Therapeutics in a report on Wednesday, October 12th. They set a “sell” rating for the company. Raymond James upped their target price on Dyne Therapeutics from $15.00 to $16.00 and gave the stock an “outperform” rating in a report on Friday, November 4th. Finally, Piper Sandler upped their target price on Dyne Therapeutics from $17.00 to $23.00 in a report on Tuesday, September 6th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $21.25.

Insider Buying and Selling

In related news, insider Joshua T. Brumm sold 14,200 shares of the company’s stock in a transaction on Friday, October 7th. The stock was sold at an average price of $13.37, for a total transaction of $189,854.00. Following the completion of the sale, the insider now directly owns 204,623 shares in the company, valued at approximately $2,735,809.51. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, insider Joshua T. Brumm sold 195,800 shares of the stock in a transaction dated Monday, October 10th. The stock was sold at an average price of $12.46, for a total value of $2,439,668.00. Following the transaction, the insider now directly owns 204,623 shares of the company’s stock, valued at $2,549,602.58. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Joshua T. Brumm sold 14,200 shares of the stock in a transaction dated Friday, October 7th. The shares were sold at an average price of $13.37, for a total value of $189,854.00. Following the completion of the transaction, the insider now directly owns 204,623 shares in the company, valued at $2,735,809.51. The disclosure for this sale can be found here. 42.34% of the stock is currently owned by company insiders.

Dyne Therapeutics Profile

(Get Rating)

Dyne Therapeutics, Inc, a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

Read More

Institutional Ownership by Quarter for Dyne Therapeutics (NASDAQ:DYN)

Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.